Compare Amphastar Pharmaceuticals Inc (AMPH) vs Charter Communications Inc (CHTR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Charter Communications Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Charter Communications Inc trades at $131.19 (market cap $16.08B). The key difference: Charter Communications Inc is far larger — about 19.5× Amphastar Pharmaceuticals Inc's market cap, and Amphastar Pharmaceuticals Inc is trading nearer its 52-week high, Charter Communications Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | CHTR | |
|---|---|---|
Market Cap | $826.08M | $16.08B |
Sector | Health | Media |
52-Week High | $30.81 | $399.61 |
52-Week Low | $16.87 | $125.54 |
Enterprise Value | $1.22B | $112.38B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Charter Communications (CHTR) trades at $130.73, down 2.69% today, with a bearish technical signal and oversold short-term RSI. The stock shows extremely low valuation multiples (P/E 3.54, P/S 0.32) against solid profitability (ROE 30.23%, net margin 9.03%), while recent news highlights potential partnerships with SpaceX and acquisition interest from Comcast. Cash flow remains positive despite high capital expenditures, though revenue growth has stagnated near $54.8B annually.
CHTR presents a deep value opportunity with significant upside to the $204.67 consensus target, but high debt ($93.21B long-term) and competitive pressures in broadband/video markets pose risks. Investor sentiment is mixed amid earnings misses, yet analyst coverage leans bullish with 47% buy ratings. The stock's trajectory hinges on operational execution and strategic developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Charter Communications Inc
Charter is the product of the 2016 merger of three cable companies, each with a decades-long history in the business: Legacy Charter, Time Warner Cable, and Bright House Networks. The firm now holds networks capable of providing television, internet access, and phone services to roughly 54 million U.S. homes and businesses, around 40% of the country. Across this footprint, Charter serves 29 million residential and 2 million commercial customer accounts under the Spectrum brand, making it the second-largest U.S. cable company behind Comcast. The firm also owns, in whole or in part, sports and news networks, including Spectrum SportsNet (long-term local rights to Los Angeles Lakers games), SportsNet LA (Los Angeles Dodgers), SportsNet New York (New York Mets), and Spectrum News NY1.
Read more on CHTR →
